Selected Publications
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA, Mamtani R, Huang AC.: CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer Nat Med Online ahead of print : 2021.
Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, Cohen AD.: B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy Br J Haematol 193 : 851-855,2021.
Raychaudhuri R, Qualtieri J, Garfall AL: Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma Am J Hematology 95 (1): E28-E30,2020.
Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melehorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma Blood Adv
3 (19): 2812-2815,2019 .
Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, Lesokhin AM: Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Adv 3 (16): 2487-2490,2019.
Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.: Prospective Study of Cardiac Evens During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 37 (22): 1946-1955,2019.
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest
129 (6): 2210-2221,2019.
Zhou N, Gutierrez-Uzquiza A, Zheng XY, Chang R, Vogl DT, Garfall AL, Bernabei L, Saraf A, Florens L, Washburn MP, Illendula A, Bushweller JH5, Busino L.: RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia 33 (8): 2006-2021,2019.
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr NDS, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 4 (4): e127684,2019.
Reed-Guy L, Hoteit MA, Garfall AL: Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18 (8): e337-e338.,2018.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-173
3400 Civic Center Blvd.
Philadelphia,
PA
19104
Phone: 215-662-7910
Patient appointments: 800-789-7366